Innovative Partnership Forged Between LSU AgCenter And GB Sciences To Advance The Understanding Of The Cannabis Plant

LAS VEGAS, Sept. 18, 2017 /PRNewswire/ — GB Sciences, Inc. (GBLX) announces that Louisiana State University (LSU) AgCenter has signed their agreement with GB Sciences Louisiana, LLC, a wholly-owned subsidiary of GB Sciences, Inc., for the production of medical cannabis products for qualifying patients.  In compliance with the Alison Neustrom Act, GB Sciences will produce medical cannabis under the AgCenter’s license. 

(PRNewsfoto/GB Sciences, Inc.)

This agreement is not only historic, but it is one that creates a truly formidable partnership. LSU is a major research University with a long and storied history as an innovator, and GB Sciences is a publicly traded cannabis company firmly rooted in science. Both organizations are dedicated to advancing the understanding of the plant and putting cannabis-based medicines in the hands of the patients of Louisiana.

To learn more:

About GB Sciences, Inc.

GB Sciences, Inc. (GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. The Company’s goal is creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. To learn more about GB Sciences, Inc., go to:

Forward-Looking Statements

This press release may contain statements relating to future results or events, which are forward-looking statements.  Words such as “expects”, “intends”, “plans”, “may”, “could”, “should”, “anticipates”, “likely”, “believes” and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company’s belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company’s control.  It is possible that the Company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements.  Further, information concerning the Company and its business, including factors that potentially could materially affect the Company’s business and financial and other results, are contained in the Company’s filings with the Securities and Exchange Commission, available at  All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

Note:  Although the Company’s research and development activities are not illegal, the production and sale of cannabis products violate federal laws as they presently exist.

Contact Information

GB Sciences, Inc., 3550 West Teco Ave., Las Vegas, NV 89118
866-721-0297, or 
Liz Bianco Publicity Director,,
Tom Arcuragi, COO,

View original content with multimedia:

Source link